€ 36.000 per year gross
Breast cancer management is hindered by extensive molecular and phenotypic heterogeneity. Despite advances in molecular stratification and precision medicine, major unmet clinical needs persist, particularly in intermediate-risk Luminal breast cancer and triple-negative breast cancer (TNBC), the most aggressive subtype.
Our laboratory has recently developed two multigene signatures: PetSign, capturing metabolic (glycolytic) alterations, and StemPrintER, reflecting the acquisition of cancer stem cell properties. This project aims to leverage these signatures to improve prognostic stratification of Luminal and TNBC patients and to identify FDA-approved drugs capable of targeting these phenotypes.